Physician profile
Robert L Segal
NPI 1104114875
$26,423.97
in general payments reported to CMS, 2019-2025
64 companies · $5,094 in 2025
The $5,094 reported for 2025 was more than what 91% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,364 · 2020: $784 · 2021: $2,898 · 2022: $3,759 · 2023: $6,428 · 2024: $5,097 · 2025: $5,094.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Travel and Lodging: $1,378 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $112 · Entertainment: $77.33 · Education: $35.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15,016.57 |
| Travel and Lodging | $1,378.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $111.79 |
| Entertainment | $77.33 |
| Education | $35.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $4,167.84 | 2019-2025 | Ams 700, Ams 800 Artificial Urinary Sphincter, Ams 700 Cxr Rte Kit |
| Teleflex LLC | $2,584.22 | 2021-2025 | Urolift, Barrigel |
| Sn Holdings, LLC | $2,085.00 | 2023 | |
| Sumitomo Pharma America, INC. | $2,010.92 | 2023-2025 | Gemtesa, Orgovyx |
| Coloplast Corp | $1,577.14 | 2019-2025 | Titan, Porges Coloplast |
| Janssen Biotech, INC. | $1,354.85 | 2019-2025 | Erleada, Akeega |
| Bayer Healthcare Pharmaceuticals INC. | $1,066.71 | 2019-2025 | |
| Astellas Pharma US INC | $1,062.90 | 2019-2024 | Myrbetriq |
| Olympus America INC. | $926.45 | 2022-2025 | Itind System, Soltive |
| Endo Pharmaceuticals INC. | $899.87 | 2019-2024 | Xiaflex, Aveed |
| Dendreon Pharmaceuticals LLC | $746.39 | 2019-2024 | Provenge |
| Ferring Pharmaceuticals INC. | $712.98 | 2019-2025 | Adstiladrin |
| Urovant Sciences INC | $445.36 | 2021-2022 | |
| Progenics Pharmaceuticals, INC. | $437.07 | 2021-2025 | Pylarify |
| Endo USA, INC. | $421.20 | 2024-2025 | Xiaflex, Aveed |
Show all 63 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $389.23 | 2019-2025 | |
| Antares Pharma, INC. | $371.87 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Abbvie INC. | $326.83 | 2019-2025 | Lupron Depot |
| Merck Sharp & Dohme LLC | $302.87 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Neotract INC. | $281.23 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $261.60 | 2023-2025 | |
| Laborie Medical Technologies Corp. | $261.17 | 2022-2025 | Optilume Bph Drug Coated Balloon Catheter |
| Myovant Sciences INC. | $257.49 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $256.45 | 2022-2025 | Lynparza, Imfinzi |
| Allergan, INC. | $251.29 | 2019-2021 | |
| Tolmar, INC. | $229.99 | 2023-2025 | Jatenzo, Eligard |
| Rigicon,INC. | $215.87 | 2023-2025 | Rigi10, Rigi10 Malleable Penile Prosthesis |
| Tolmar Pharmaceuticals, INC. | $200.80 | 2019-2022 | |
| Calyxo, INC. | $183.29 | 2024-2025 | Cvac Aspiration System |
| Accord Healthcare, INC. | $159.48 | 2024-2025 | |
| Urogen Pharma, INC. | $145.52 | 2021-2025 | |
| Blue Earth Diagnostics | $133.51 | 2019-2025 | Posluma |
| Immunitybio, INC. | $129.55 | 2024-2025 | |
| Tempus Ai, INC | $122.97 | 2024-2025 | Xt Cdx |
| Telix Pharmaceuticals | $114.09 | 2023 | Illuccix |
| Procept Biorobotics Corporation | $100.41 | 2021 | |
| Innovation Technologies INC | $96.51 | 2022 | |
| Sun Pharmaceutical Industries INC. | $95.49 | 2019-2025 | |
| Medtronic, INC. | $95.00 | 2023 | Interstim |
| Halozyme INC | $92.14 | 2023 | |
| Medtronic USA, INC. | $91.77 | 2019 | |
| Janssen Scientific Affairs, LLC | $68.48 | 2019-2020 | |
| C. R. Bard, INC. & Subsidiaries | $68.30 | 2024-2025 | Magic3 Go Intermittent Urinary Catheter |
| Novo Nordisk INC | $67.32 | 2024 | Rivfloza |
| Amgen INC. | $63.30 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $54.71 | 2025 | Opdivo |
| Clarus Therapeutics INC. | $50.83 | 2021 | |
| Dentsply Ih Ab | $44.25 | 2025 | Lofric |
| Caris Mpi, INC. | $37.54 | 2025 | Mi Cancer Seek |
| Exelixis INC. | $34.61 | 2025 | Cabometyx |
| Axonics, INC. | $30.42 | 2024 | Axonics |
| Clovis Oncology, INC. | $27.12 | 2020 | |
| Acerus Pharmaceuticals Corporation | $26.83 | 2022 | |
| Myriad Genetic Laboratories, INC. | $26.65 | 2021 | |
| Foundation Medicine, INC. | $26.43 | 2021-2022 | |
| Vertex Pharmaceuticals Incorporated | $19.24 | 2025 | |
| Rochester Medical Corporation | $18.94 | 2021 | |
| Bioprotect Medical, INC. | $18.67 | 2025 | Bioprotect Balloon Implant System |
| Verity Pharmaceuticals INC. | $17.36 | 2025 | Trelstar |
| Travere Therapeutics, INC. | $17.36 | 2019 | |
| Acacia Pharma INC | $14.94 | 2021 | |
| Hollister Incorporated | $14.08 | 2023 | Infyna Chic, Vapro |
| Metuchen Pharmaceuticals | $11.27 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$361,837.72 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Segal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.